Hematopathology
Subrata Pal; Kingshuk Bose; Abhishek Sharma; Mrinal Sikder
Volume 11, Issue 5 , October 2016, , Pages 474-477
Abstract
Colorectal carcinoma is a common malignancy in India as well as in world. Inspite of its high metastasizing ability to various organs and lymph node, orbital metastasis is exceptional. Very few cases have been reported in the world literature. We report orbital metastasis in a case of moderately differentiated ...
Read More
Colorectal carcinoma is a common malignancy in India as well as in world. Inspite of its high metastasizing ability to various organs and lymph node, orbital metastasis is exceptional. Very few cases have been reported in the world literature. We report orbital metastasis in a case of moderately differentiated rectal adenocarcinoma in a 58-year male patient from India in 2015. We want to focus on the rare metastatic pathway of rectal adenocarcinoma and early diagnosis of the orbital metastasis, which can help in application of therapy to save the eyesight.
Ali Yaghoubi; Payam Azadeh; KhosroM M Sheibani; Mohammad Foudazi; Behrouz Shafaghi; Manouchehr Davaei
Volume 6, Issue 3 , June 2011, , Pages 110-116
Abstract
Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection).
Materials and Methods: Seventy-five consecutive ...
Read More
Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection).
Materials and Methods: Seventy-five consecutive patients with the diagnosis of advanced rectal adenocarcinoma were included. Two basic chemotherapy regimens were used: one drug (5-FU or Xeloda) or two-drug (5-U or Xeloda with Eloxatin). Endpoints were pCR and preservation of sphincter during surgery through low anterior resection (LAR). All analyses were done using SPSS software version 17.0 (SPSS Inc., Chicago, IL).
Results: There were no significant differences between the group of patients who received one-drug regimen with those who received two-drug regimen regarding the pCR (four cases (23.5%) versus 25 vases (43.1%)) state or the type of surgery performed [nine cases (52.9%) versus 36 cases (62.1%)].
Conclusion: Adding Eloxatin to the standard treatment of rectal adenocarcinoma (5-FU based) did not yield in a higher pCR or a higher chance to preserve the anal sphincter.
